AZD4248

AZD4248 is an investigational drug being developed by **AstraZeneca** for the treatment of **diabetic kidney disease**. It is being evaluated in both **oral solution** and **intravenous infusion** formulations. A phase I clinical study is underway to investigate its **safety, tolerability, pharmacokinetics, and pharmacodynamics** in healthy participants and in individuals with chronic kidney disease. The precise molecular target and mechanism of action have not been publicly disclosed as of the latest available data. The drug is administered orally in current human studies, focusing on establishing initial safety and dosing parameters in early-stage clinical development[5][6][9].